BRONKOSOL
Clinical safety rating
cautionComprehensive clinical and safety monograph for BRONKOSOL (BRONKOSOL).
Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular cAMP, leading to smooth muscle relaxation in the airways.
| Metabolism | Primarily hepatic via catechol-O-methyltransferase (COMT); also undergoes sulfate conjugation. |
| Excretion | Primarily renal excretion as sulfate conjugates; unchanged drug accounts for <10% of excretion. Biliary/fecal excretion is minimal (<2%). |
| Half-life | Terminal elimination half-life is 3–4 hours; prolonged in hepatic impairment (up to 8 hours). |
| Protein binding | 40–60% bound to albumin, with some binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Approximately 0.5 L/kg, indicating distribution into total body water and moderate tissue binding. |
| Bioavailability | Inhalation: 10–20% (variable due to deposition and first-pass metabolism); oral: <1% due to extensive first-pass metabolism. |
| Onset of Action | Inhalation: 5–15 minutes; oral: 30–60 minutes. |
| Duration of Action | Inhalation: 3–4 hours; oral: 4–6 hours. Duration may be shorter with repeated use due to tachyphylaxis. |
| Molecular Weight | 239.31 |
2.5 mg (0.5 mL of 0.5% solution) via nebulization three to four times daily, as needed.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; use caution in severe hepatic impairment. |
| Pediatric use | 0.01-0.03 mL/kg of 0.5% solution (maximum 0.5 mL) via nebulization every 4-6 hours as needed. |
| Geriatric use | Initiate at lowest effective dose; monitor for tachycardia and hypertension. |
| 1st trimester | Isoetharine is a beta-2 adrenergic agonist; limited human data. Animal studies show fetal risk? No adequate studies. Use only if potential benefit justifies potential risk. |
| 2nd trimester | Same as t1. Generally avoid during pregnancy unless necessary for asthma control. |
| 3rd trimester | Beta-agonists may delay labor; use with caution. Risk of maternal tachycardia and fetal tachycardia. |
Clinical note
Comprehensive clinical and safety monograph for BRONKOSOL (BRONKOSOL).
| Placental transfer | Isoetharine crosses the placenta; extent not well documented but expected due to low molecular weight. |
| Breastfeeding | Excretion into breast milk is unknown; however, due to poor oral bioavailability, infant exposure likely minimal. Use with caution, especially in preterm neonates. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category C. In first trimester, limited data; animal studies show no teratogenicity at high doses. Second and third trimesters: no known fetal risks from inhaled bronchodilator use; systemic exposure minimal. However, uncontrolled asthma poses greater risk (maternal hypoxia, preterm birth). |
| Fetal Monitoring | Monitor maternal pulmonary function, heart rate, blood pressure, and signs of asthma exacerbation. Fetal assessment: ultrasound for growth and amniotic fluid volume if severe asthma. No specific fetal monitoring required for drug. |
| Fertility Effects | No known adverse effects on fertility. Animal studies show no impairment at doses up to 25 times maximum human inhalation dose. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to isoetharine or any componentTachyarrhythmiasHypertrophic obstructive cardiomyopathy
| Precautions | Paradoxical bronchospasm may occur with excessive use, Cardiovascular effects: tachycardia, hypertension, arrhythmias, Hypokalemia may occur with high doses, Caution in patients with hyperthyroidism, diabetes mellitus, or seizure disorders |
| Food/Dietary | No significant food interactions. Avoid excessive caffeine intake as it may increase beta-agonist side effects (tremor, tachycardia). No specific dietary restrictions. |
| Clinical Pearls | Bronkosol (isoetharine) is a beta-2 selective bronchodilator, but with less beta-2 selectivity than albuterol; monitor for tachycardia and tremor. It is administered via nebulization; ensure proper equipment and technique. Onset within 2-5 minutes, duration 1-3 hours. Not a first-line agent; use primarily for acute bronchospasm when albuterol is unavailable. Paradoxical bronchospasm can occur; discontinue if worsens. |
| Patient Advice | Use exactly as prescribed; do not increase dose or frequency without consulting your doctor. · If you miss a dose, use it as soon as you remember, but skip if it's almost time for the next dose; do not double up. · Rinse your mouth with water after each use to prevent dryness and irritation. · Seek immediate medical help if symptoms worsen or you experience chest pain, fast heartbeat, or difficulty breathing after use. · Store at room temperature away from moisture and heat; keep nebulizer clean per instructions. |
Loading safety data…